Aloxi, Palonosetron (palonosetron) is a small molecule pharmaceutical. Palonosetron was first approved as Aloxi on 2003-07-25. It has been approved in Europe to treat nausea, neoplasms, and vomiting. The pharmaceutical is active against 5-hydroxytryptamine receptor 3A. Aloxi's patent is valid until 2024-01-30 (FDA).
|Indication||nausea, neoplasms, vomiting|
|Drug Class||Serotonin 5-HT3 antagonists|